Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

ConditionAcute Myocardial Infarction

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorPharmicell Co., Ltd.

About this trial

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Those who had administered Hearticellgram-AMI

Those who voluntarily agreed in writing to participate in this investigation

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

Hearticellgram-AMI
Biological/Vaccine
Patients who had administered Hearticellgram-AMI.

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: Hearticellgram-AMIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Rate of AESI

death, neoplasms or malignancies in tissues or organs, Immune response

Time frame

For 5 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pharmicell Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov

Apply now